Correlation
The correlation between AMRX and CORT is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
AMRX vs. CORT
Compare and contrast key facts about Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AMRX or CORT.
Performance
AMRX vs. CORT - Performance Comparison
Loading data...
Key characteristics
AMRX:
0.22
CORT:
1.22
AMRX:
0.82
CORT:
4.03
AMRX:
1.09
CORT:
1.55
AMRX:
0.15
CORT:
4.00
AMRX:
1.21
CORT:
10.24
AMRX:
10.92%
CORT:
17.78%
AMRX:
35.65%
CORT:
121.27%
AMRX:
-97.52%
CORT:
-94.28%
AMRX:
-85.77%
CORT:
-32.03%
Fundamentals
AMRX:
$3.39B
CORT:
$8.23B
AMRX:
-$0.04
CORT:
$1.16
AMRX:
1.20
CORT:
12.01
AMRX:
86.10
CORT:
12.05
AMRX:
$2.83B
CORT:
$685.45M
AMRX:
$1.04B
CORT:
$674.70M
AMRX:
$565.78M
CORT:
$111.33M
Returns By Period
In the year-to-date period, AMRX achieves a -7.83% return, which is significantly lower than CORT's 54.08% return. Over the past 10 years, AMRX has underperformed CORT with an annualized return of -17.32%, while CORT has yielded a comparatively higher 28.74% annualized return.
AMRX
-7.83%
-5.81%
-12.57%
7.67%
28.26%
8.43%
-17.32%
CORT
54.08%
6.02%
32.49%
146.24%
54.63%
38.67%
28.74%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AMRX vs. CORT — Risk-Adjusted Performance Rank
AMRX
CORT
AMRX vs. CORT - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
AMRX vs. CORT - Dividend Comparison
Neither AMRX nor CORT has paid dividends to shareholders.
Drawdowns
AMRX vs. CORT - Drawdown Comparison
The maximum AMRX drawdown since its inception was -97.52%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AMRX and CORT.
Loading data...
Volatility
AMRX vs. CORT - Volatility Comparison
Amneal Pharmaceuticals, Inc. (AMRX) has a higher volatility of 10.65% compared to Corcept Therapeutics Incorporated (CORT) at 9.39%. This indicates that AMRX's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
AMRX vs. CORT - Financials Comparison
This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AMRX vs. CORT - Profitability Comparison
AMRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a gross profit of 255.89M and revenue of 695.42M. Therefore, the gross margin over that period was 36.8%.
CORT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a gross profit of 154.81M and revenue of 157.21M. Therefore, the gross margin over that period was 98.5%.
AMRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported an operating income of 100.35M and revenue of 695.42M, resulting in an operating margin of 14.4%.
CORT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported an operating income of 3.42M and revenue of 157.21M, resulting in an operating margin of 2.2%.
AMRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Amneal Pharmaceuticals, Inc. reported a net income of 12.20M and revenue of 695.42M, resulting in a net margin of 1.8%.
CORT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Corcept Therapeutics Incorporated reported a net income of 20.29M and revenue of 157.21M, resulting in a net margin of 12.9%.